These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
76 related articles for article (PubMed ID: 21699803)
1. No impact of hepatitis C virus infection on mortality among drug users during the first decade after seroconversion. Grady B; van den Berg C; van der Helm J; Schinkel J; Coutinho R; Krol A; Prins M Clin Gastroenterol Hepatol; 2011 Sep; 9(9):786-792.e1. PubMed ID: 21699803 [TBL] [Abstract][Full Text] [Related]
2. Impact of hepatitis C virus infection on all-cause and liver-related mortality in a large community-based cohort of inner city residents. Grebely J; Raffa JD; Lai C; Kerr T; Fischer B; Krajden M; Dore GJ; Tyndall MW J Viral Hepat; 2011 Jan; 18(1):32-41. PubMed ID: 20196806 [TBL] [Abstract][Full Text] [Related]
3. Mortality in HIV-infected injection drug users with active vs cleared hepatitis C virus-infection: a population-based cohort study. Omland LH; Jepsen P; Weis N; Christensen PB; Laursen AL; Nielsen H; Krarup H; Sørensen HT; Obel N J Viral Hepat; 2010 Apr; 17(4):261-8. PubMed ID: 19709359 [TBL] [Abstract][Full Text] [Related]
4. Mortality in patients with chronic and cleared hepatitis C viral infection: a nationwide cohort study. Omland LH; Krarup H; Jepsen P; Georgsen J; Harritshøj LH; Riisom K; Jacobsen SE; Schouenborg P; Christensen PB; Sørensen HT; Obel N; J Hepatol; 2010 Jul; 53(1):36-42. PubMed ID: 20400197 [TBL] [Abstract][Full Text] [Related]
5. All-cause and liver-related mortality in hepatitis C infected drug users followed for 33 years: a controlled study. Kielland KB; Skaug K; Amundsen EJ; Dalgard O J Hepatol; 2013 Jan; 58(1):31-7. PubMed ID: 22960427 [TBL] [Abstract][Full Text] [Related]
6. Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971 to 1975. Rodger AJ; Roberts S; Lanigan A; Bowden S; Brown T; Crofts N Hepatology; 2000 Sep; 32(3):582-7. PubMed ID: 10960453 [TBL] [Abstract][Full Text] [Related]
7. Epidemiology of hepatitis C virus among long-term dialysis patients: a 9-year study in an Italian region. Di Napoli A; Pezzotti P; Di Lallo D; Petrosillo N; Trivelloni C; Di Giulio S; Am J Kidney Dis; 2006 Oct; 48(4):629-37. PubMed ID: 16997059 [TBL] [Abstract][Full Text] [Related]
8. Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study. Bruno S; Zuin M; Crosignani A; Rossi S; Zadra F; Roffi L; Borzio M; Redaelli A; Chiesa A; Silini EM; Almasio PL; Maisonneuve P Am J Gastroenterol; 2009 May; 104(5):1147-58. PubMed ID: 19352340 [TBL] [Abstract][Full Text] [Related]
9. Attribution of hepatitis C virus seroconversion risk in young injection drug users in 5 US cities. Hagan H; Pouget ER; Williams IT; Garfein RL; Strathdee SA; Hudson SM; Latka MH; Ouellet LJ J Infect Dis; 2010 Feb; 201(3):378-85. PubMed ID: 20053137 [TBL] [Abstract][Full Text] [Related]
10. Hepatitis C virus reinfection in injection drug users. Grebely J; Conway B; Raffa JD; Lai C; Krajden M; Tyndall MW Hepatology; 2006 Nov; 44(5):1139-45. PubMed ID: 17058216 [TBL] [Abstract][Full Text] [Related]
11. Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users. Miller CL; Johnston C; Spittal PM; Li K; Laliberté N; Montaner JS; Schechter MT Hepatology; 2002 Sep; 36(3):737-42. PubMed ID: 12198668 [TBL] [Abstract][Full Text] [Related]
12. Impact of HCV infection on first cadaveric renal transplantation, a single center experience. Lin HH; Huang CC; Huang JY; Yang CW; Wu MS; Fang JT; Yu CC; Chiang YJ; Chu SH Clin Transplant; 2004 Jun; 18(3):261-6. PubMed ID: 15142046 [TBL] [Abstract][Full Text] [Related]
13. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. Rockstroh JK; Mocroft A; Soriano V; Tural C; Losso MH; Horban A; Kirk O; Phillips A; Ledergerber B; Lundgren J; J Infect Dis; 2005 Sep; 192(6):992-1002. PubMed ID: 16107951 [TBL] [Abstract][Full Text] [Related]
14. Sexual and other noninjection risks for HBV and HCV seroconversions among noninjecting heroin users. Neaigus A; Gyarmathy VA; Zhao M; Miller M; Friedman SR; Des Jarlais DC J Infect Dis; 2007 Apr; 195(7):1052-61. PubMed ID: 17330797 [TBL] [Abstract][Full Text] [Related]
15. Long-term outcome of hepatitis C infection after liver transplantation. Gane EJ; Portmann BC; Naoumov NV; Smith HM; Underhill JA; Donaldson PT; Maertens G; Williams R N Engl J Med; 1996 Mar; 334(13):815-20. PubMed ID: 8596547 [TBL] [Abstract][Full Text] [Related]
16. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Chiaramonte M; Stroffolini T; Vian A; Stazi MA; Floreani A; Lorenzoni U; Lobello S; Farinati F; Naccarato R Cancer; 1999 May; 85(10):2132-7. PubMed ID: 10326690 [TBL] [Abstract][Full Text] [Related]
17. Mortality in siblings of patients coinfected with HIV and hepatitis C virus. Hansen AB; Gerstoft J; Kronborg G; Pedersen C; Sorensen HT; Obel N J Infect Dis; 2007 Jan; 195(2):230-5. PubMed ID: 17191168 [TBL] [Abstract][Full Text] [Related]
18. Low risk for hepatitis C seroconversion in methadone maintenance treatment. Peles E; Schreiber S; Rados V; Adelson M J Addict Med; 2011 Sep; 5(3):214-20. PubMed ID: 21844836 [TBL] [Abstract][Full Text] [Related]
19. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. Maher L; Jalaludin B; Chant KG; Jayasuriya R; Sladden T; Kaldor JM; Sargent PL Addiction; 2006 Oct; 101(10):1499-508. PubMed ID: 16968352 [TBL] [Abstract][Full Text] [Related]
20. The incidence and risk factors of community-acquired hepatitis C in a cohort of Italian blood donors. Prati D; Capelli C; Silvani C; De Mattei C; Bosoni P; Pappalettera M; Mozzi F; Colombo M; Zanella A; Sirchia G Hepatology; 1997 Mar; 25(3):702-4. PubMed ID: 9049222 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]